Factors influencing treatment efficacy of 24-week combination therapy with interferon α-2b plus ribavirin for chronic hepatitis C

Digestive Diseases and Sciences

Volumn 52, Issue 9, 2007, Pages 2418-2426

  Moriyama, Mitsuhiko ^a   Matsumura, Hiroshi ^a   Nirei, Kazushige ^a   Arakawa, Yasuo ^a   Yamagami, Hiroaki ^a   Ogawa, Masahiro ^a   Kaneko, Miki ^a   Matsuoka, Shuichi ^a   Amaki, Shuichi ^a   Tanaka, Naohide ^a   Arakawa, Yasuyuki ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic hepatitis C; Interferon 2b; Ribavirin; Sustained virological response; Total dose of ribavirin per body weight

Indexed keywords

ALPHA2B INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; BIOPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOENZYME TECHNIQUES; INTERFERON ALFA-2A; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 34547839685     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9693-0     Document Type: Article

References (16)

1. Di Bisceglie AM, Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH (1989) Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 321:1506-1510
2. Moriyama M, Matsumura H, Aoki H, Shimizu T, Nakai K, Saito T, Yamagami H, Shioda A, Kaneko M, Goto I, Tanaka N, Arakawa Y (2003) Long-term outcome, with monitoring of platelet counts, in patients with chronic hepatitis C and liver cirrhosis after interferon therapy. Intervirology 46:296-307
3. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J (1998) Randomised trial of interferon alpha2b + ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b + placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352:1426-1432
4. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yana M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M (1999) Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 131:174-181
5. Shiratori Y, Moriyama M, Imazeki F, Ohkubo H, Tanaka N, Arakawa Y, Yoshida H, Yokosuka O, Shibuya A, Matsuzaki K, Hashimoto E, Hayashi N, Hirata K, Ohashi Y, Omata M (2000) A prospective study of interferon therapy modified by pre-treatment viral load in cirrhotic patients. Tokyo-Chiba Hepatitis Res Group Liver 20:271-280
6. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S (1995) Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346(8982):1051-1055
7. Tsubota A, Arase Y, Suzuki F, Suzuki Y, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kumada H (2004) High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load. J Gastroenterol 39:155-161
8. Bressler BL, Guindi M, Tomlinson G, Heathcote J (2003) High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38:639-644
9. Almasio PL (2004) Weight-based dosing: Which impact on efficacy and safety of therapy? Dig Liver Dis 36 (Suppl 3):S349-S353
10. Okamoto H, Sugiyama Y, Okada S et al (1992) Typing of hepatitis C virus by PCR with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 73:673-679
11. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ (1994) Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19:1513-1520
12. Bruno R, Sacchi P, Maiocchi L, Zocchetti C, Ciappina V, Patruno S, Filice G (2005) Area-under-the-curve for peginterferon alpha-2a and peginterferon alpha-2b is not related to body weight in treatment-naive patients with chronic hepatitis C. Antivir Ther 10(2):201-205
13. Chander G, Sulkowski MS, Jenckes MW, Torbenson MS, Herlong HF, Bass EB, Gebo KA (2002) Treatment of chronic hepatitis C: a systematic review. Hepatology 36(5; Suppl 1):S135-S144
14. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK, Hepatitis Interventional Therapy Group (2001) A randomized, double-blind trial comparing pegylated interferon alpha-2b to interferon alpha-2b as initial treatment for chronic hepatitis C. Hepatology 34:395-403
15. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J (1998) Randomised trial of interferon alpha2b+ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b+placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352:1426-1432
16. Manns MP, McHutchison JG, Gordon SC et al (2001) Peginterferon alpha-2b+ribavirin compared with interferon alpha-2b+ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965